Rapid Micro Biosystems, Inc.
RPID Healthcare Medical Devices
Rapid Micro Biosystems, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.6 million, up 19.7% from fiscal 2024. In the quarter to June 2026, revenue grew 10.9%, EPS was flat and free cash flow fell 24.0%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow RPID
Rapid Micro Biosystems, Inc. (RPID) Altman Z-score
Rapid Micro Biosystems, Inc.'s Altman Z-score for fiscal 2025 is −8.86, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −8.86 | (2.50) |
| FY2024 | −6.36 | (2.64) |
| FY2023 | −3.73 | (1.80) |
| FY2022 | −1.93 | (6.80) |
| FY2021 | 4.87 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.57 | — | 0.68 | |
| Retained earnings / total assets | (6.98) | — | −9.77 | |
| EBIT / total assets | (0.63) | — | −2.09 | |
| Market value of equity / total liabilities | 3.11 | — | 1.87 | |
| Sales / total assets | 0.45 | — | 0.45 | |
| Altman Z-score | Distress zone | −8.86 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −22.43 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| SRTS Sensus Healthcare, Inc. compare | 8.9× |
| XTNT Xtant Medical Holdings, Inc. compare | 0.0× |
| NNOX Nano-X Imaging Ltd. compare | −0.2× |
| SNWV Sanuwave Health Inc. compare | −3.0× |
| MDAI Spectral AI, Inc. compare | −3.3× |
| TELA TELA Bio, Inc. compare | −5.9× |
| CVRX CVRx, Inc. compare | −6.3× |
| RPID Rapid Micro Biosystems, Inc. | −8.9× |
| TLIS Talis Biomedical Corporation compare | −9.1× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets